Commentary

Topoisomerases as targets in acute leukemia: I, II, I plus II or none?

Sami N. Malek, Steven D. Gore

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalLeukemia Research
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Neoplasm Proteins
Neoplasm DNA
Neoplasm Drug Resistance
Antineoplastic Combined Chemotherapy Protocols
Topotecan
Remission Induction
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Clinical Trials, Phase I
Enzyme Inhibitors
Acute Disease
Etoposide
Antineoplastic Agents
Leukemia
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Commentary : Topoisomerases as targets in acute leukemia: I, II, I plus II or none? / Malek, Sami N.; Gore, Steven D.

In: Leukemia Research, Vol. 27, No. 1, 01.01.2003, p. 1-3.

Research output: Contribution to journalArticle

Malek, Sami N. ; Gore, Steven D. / Commentary : Topoisomerases as targets in acute leukemia: I, II, I plus II or none?. In: Leukemia Research. 2003 ; Vol. 27, No. 1. pp. 1-3.
@article{713a9d2d35164ca2ab4448b247820c93,
title = "Commentary: Topoisomerases as targets in acute leukemia: I, II, I plus II or none?",
author = "Malek, {Sami N.} and Gore, {Steven D.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0145-2126(02)00219-9",
language = "English (US)",
volume = "27",
pages = "1--3",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Commentary

T2 - Topoisomerases as targets in acute leukemia: I, II, I plus II or none?

AU - Malek, Sami N.

AU - Gore, Steven D.

PY - 2003/1/1

Y1 - 2003/1/1

UR - http://www.scopus.com/inward/record.url?scp=0037212028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037212028&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00219-9

DO - 10.1016/S0145-2126(02)00219-9

M3 - Article

VL - 27

SP - 1

EP - 3

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -